PD-1与PD-L1抑制剂在非小细胞肺癌中的肺炎发生率:系统综述与荟萃分析
结果显示PD-1抑制剂任何级别肺炎发生率3.6%高于PD-L1抑制剂的1.3%,3-4级肺炎发生率1.1%也高于0.4%;初治患者1-4级肺炎发生率4.3%高于经治患者的2.8%。
要点
- PD-1抑制剂任何级别肺炎发生率3.6%,显著高于PD-L1抑制剂的1.3%。
- PD-1抑制剂3-4级肺炎发生率1.1%,高于PD-L1抑制剂的0.4%。
- 初治患者1-4级肺炎发生率4.3%,高于经治患者的2.8%。
核心结论
- PD-1抑制剂相比PD-L1抑制剂有更高的肺炎发生率。
- 初治患者肺炎发生率高于经治患者。
研究设计与样本
- 纳入nivolumab、pembrolizumab、atezolizumab、durvalumab和avelumab单药治疗NSCLC的临床试验。
- 采用DerSimonian-Laird随机效应模型计算肺炎发生率。
临床怎么用
- 使用PD-1抑制剂时应比PD-L1抑制剂更警惕肺炎发生。
- 对初治患者应加强肺炎监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Programmed death 1 (PD-1) programmed death-ligand 1 (PD-L1) inhibitors show significant clinical activity in non-small cell lung carcinoma (NSCLC). However, they are often associated with potentially fatal immune-mediated pneumonitis. Preliminary reports of trials suggest a difference in the rate of pneumonitis with PD-1 and PD-L1 inhibitors. We sought to determine the overall incidence of pneumonitis and differences according to type of inhibitors and prior chemotherapy use. METHODS: MEDLINE, Embase, and Scopus databases were searched up to November 2016. Rates of pneumonitis of any grade and grade ≥ 3 from all clinical trials investigating nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab as single agents in NSCLC were collected. The incidence of pneumonitis across trials was calculated using DerSimonian-Laird random effects models. We compared incidences between PD-1 and PD-L1 inhibitors and between treatment naive and previously treated patients. RESULTS: Nineteen trials (12 with PD-1 inhibitors [n = 3,232] and 7 with PD-L1 inhibitors [n = 1,806]) were identified. PD-1 inhibitors were found to have statistically significant higher incidence of any grade pneumonitis compared with PD-L1 inhibitors (3.6%; 95% CI, 2.4%-4.9% vs 1.3%; 95% CI, 0.8%-1.9%, respectively; P = .001). PD-1 inhibitors were also associated with higher incidence of grade 3 or 4 pneumonitis (1.1%; 95% CI, 0.6%-1.7% vs 0.4%; 95% CI, 0%-0.8%; P = .02). Treatment naive patients had higher incidence of grade 1 through 4 pneumonitis compared with previously treated patients (4.3%; 95% CI, 2.4%-6.3% vs 2.8%; 95% CI, 1.7%- 4%; P = .03). CONCLUSIONS: There was a higher incidence of pneumonitis with use of PD-1 inhibitors compared with PD-L1 inhibitors. Higher rate of pneumonitis was more common in treatment naive patients.
引用
- Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials. Chest. 2017. PMID: 28499515. doi:10.1016/j.chest.2017.04.177
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。